Drug intelligence / Profile preview

M-Gard

Development stage
Unknown
Lead developer
Lallemand
Modality
Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

M-Gard is a highly purified, proprietary **beta-1,3/1,6-glucan** isolated from the cell wall of baker’s yeast (Saccharomyces cerevisiae), designed as an immunomodulatory dietary supplement. Its distinguishing features include a unique molecular structure with a beta-1,3-glucose backbone and long beta-1,6-branched side chains, resulting in especially potent bioactivity compared to other beta-glucans[1][2][8]. M-Gard acts primarily by modulating and training the innate immune system: it interacts with immune cell receptors, enhances immune cell activation, and promotes healthy inflammatory responses[1][2][5][8]. This “immune training” leads to a stronger and faster response to future challenges from pathogens. M-Gard is extensively studied, with human clinical trials demonstrating benefits including reduced incidence, duration, and severity of respiratory tract infections and allergies, as well as improved vigor in periods of stress[1][2][3][4][5][8]. It is often used in functional foods, beverages, and dietary supplements, and can serve as a vaccine adjuvant[1][4]. M-Gard is produced under strict GMP conditions, is gluten-free, vegan, non-GMO, and has Self-Affirmed GRAS status[1][2][4][8].

Brand names
M-Gard
Other names
yeast beta-1,3/1,6-glucanbioactive beta-glucanbaker’s yeast beta-glucan
02

Targets

αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)

Beyond the preview

Go deeper on M-Gard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-Gard.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call